Vera Therapeutics Announces Executive Changes
Vera Therapeutics has announced the following executive changes:
- Joanne Curley has joined as Chief Development Officer. She was most recently Vice President of Project and Portfolio Management at Gilead Sciences after serving in various executive level roles with the company. She began her career as a Scientist with Inhale Therapeutic Systems, then with Nektar Therapeutics.
- Lauren Frenz has been named Chief Business Officer. She previously served as the company’s Senior Vice President of Corporate Strategy and Finance. Prior to that, she held multiple leadership positions with Gilead Sciences, ultimately serving as Associate Director of HIV Marketing. She started her career in strategic advisory roles with Leerink Partners.
- Tom Doan has become Senior Vice President of Clinical Operations. He was previously with Gilead Sciences, where he was most recently Executive Director of Clinical Operations, Therapeutic Area Head, Inflammation/Respiratory. He also gained experience through his roles with Genentech and Quintiles.
Vera Therapeutics is a clinical-stage biotechnology company focused on transforming patients’ lives by developing and commercializing treatments for immunological and inflammatory diseases. The company is based in San Francisco, CA.